Replies to post #27747 on MindMaze Therapeutics Holding (RLFTF)

[elllk]

Dr Javitt does say in his Sep 30, 2020 interview with Dr Yo that Aviptadil targets the VPAC1 receptor that is in the lung as opposed to the VPAC2 receptor that is in the blood vessels.

[tcm55]

Their expectations for COVID were not met but other things are being done there with VIP.
Out some there @3.35 this am and bought here @.52. Bottom.?... We'll see how well this VIP works for COVID and Lung issues with expected good DATA soon from apparently full enrollment in the IV / (EUA?) Trials.
"Expanded Access intermediate size population" is that designation NOW which was "Expanded Access personal use" ('EUA') before the Oct 22 CT.gov update.
Also combining this makes the PR totals match better. We'll see if that is significant.?.
Then IPO with nrx to NYSE for Phase 3.?...GLTA...

[Inelgr]

In post 27700, you stated:

RLF-100 targets the lungs and the VPAC1 receptor (which is tied to COVID19). The other failed drug (from PhaseBIO) targets the blood vessels (VPAC2 receptor) and treating high blood pressure

As stated in post 27731, according to the Relief Therapeutics website, - it activates BOTH the VPAC1 and VPAc2 receptors (not "just" VPAC1).